Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
RegulatoryapprovedKeytruda SCPositive
AI Analysis
Summary
Halozyme won an injunction in the Dutch patent court stopping Merck from manufacturing and selling Keytruda SC in multiple European markets due to infringement of Halozyme's MDASE patent EP 2,797,622.
Outcome Details
Dutch patent court of the Hague found Merck to be infringing Halozyme's MDASE patent EP 2,797,622 and ordered Merck to stop manufacture and sale of Keytruda SC in multiple European markets
Importance:8/10
Sentiment:
0.90
patent litigationinjunctionintellectual propertyEuroperegulatory
Read the original article
Published by PR Newswire Biotech on October 7, 2026 12:30 PM